Rivfloza® (nedosiran) – Expanded indication
March 27, 2025 - The FDA approved Novo Nordisk’s Rivfloza (nedosiran) to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2.
Top